KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cinemark Holdings (CNK) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Cinemark Holdings (CNK) over the last 17 years, with Q3 2025 value amounting to $600000.0.

  • Cinemark Holdings' Asset Writedowns and Impairment changed N/A to $600000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 1777.78%. This contributed to the annual value of $1.5 million for FY2024, which is 9096.39% down from last year.
  • Cinemark Holdings' Asset Writedowns and Impairment amounted to $600000.0 in Q3 2025.
  • Cinemark Holdings' 5-year Asset Writedowns and Impairment high stood at $92.3 million for Q2 2022, and its period low was $600000.0 during Q3 2025.
  • For the 5-year period, Cinemark Holdings' Asset Writedowns and Impairment averaged around $17.9 million, with its median value being $6.0 million (2021).
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first soared by 40075.19% in 2022, then plummeted by 9324.32% in 2023.
  • Over the past 5 years, Cinemark Holdings' Asset Writedowns and Impairment (Quarter) stood at $13.3 million in 2021, then surged by 400.75% to $66.6 million in 2022, then plummeted by 93.24% to $4.5 million in 2023, then tumbled by 66.67% to $1.5 million in 2024, then tumbled by 60.0% to $600000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $600000.0 for Q3 2025, versus $1.6 million for Q2 2025 and $1.5 million for Q4 2024.